Principles of drug therapy for acute bacterial rhinosinusitis: from evidence-based medicine to practice

Abstract

The problem of treatment of acute rhinosinusitis (ARS) is extremely important due to high prevalence of the disease. According to statistical data the ARS affects from 6% to 15% of population and does not show any tendency to reduction. These figures are associated with a high rate of acute respiratory viral infection (ARVI) which directly leads to rhinosinusitis. But, however, despite the fact that practically every individual experiences from 2 to 5 episodes of ARVI every year, only 0.5-2% of them are complicated with acute bacterial rhinosinusitis (ABRS). Despite this low percentage of bacterial infection, in 80% of cases systemic antibacterial treatment is prescribed which further worsens the problem of bacterial resistance in the world. The main difficulty in determination of therapeutic approach to ABRS is associated with absence of reliable methods of differential diagnostics of viral and bacterial etiology of the disease. Because of low sensitivity and specificity, none of additional visualization methods of ABRS diagnosing such as radiography, ultrasonography, computed tomography, can be used as a routine laboratory method. Thus, the main method of differential diagnostics of viral and bacterial ARS remains analysis of clinical data which leads to a high rate of diagnostic errors and to polypragmacy.

Nowadays there exists a wide range of medications for treatment of ABRS in the pharmacological market. The choice of therapeutic approach by our international colleagues is mostly based on the requirements of evidence-based medicine. Russian scientists, besides evidence-based medicine principles take into account the pathogenesis of the disease.

In this article different groups of medications for treatment of ABRS are presented. Some of them do not meet the requirements of evidence-based medicine so far, but they are included to the Russian standards and are used for management of ABRS.

Keywords

acute rhinosinusitis / bacterial infection / evidence-based medicine

References

[1] 1.Zabolevaemost' naseleniya Rossii v 2007 g.: statisticheskie dannye. Part I. Moscow: Minzdravsotsrazvitiya Rossii; 2008. (In Russ).

[2] Заболеваемость населения России в 2007 г.: статистические данные. Ч. I. М.: Минздравсоцразвития России, 2008.

[3] 2.Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusiyis and nasal polyps 2012. A sum-mary for otorhinolaryngologists. Rhinology. 2012; 50(1):1-12. doi: 10.4193/Rhino50E2.

[4] Fokkens W.J., Lund V.J., Mullol J., et al. EPOS 2012: European position paper on rhinosinusiyis and nasal polyps, 2012. A summary for otorhinolaryngologists // Rhinology. 2012. Vol. 50, №1. P. 1-12. doi: 10.4193/Rhino50E2.

[5] 3.Lopatin AS, Gamov VP. Ostryi i khronicheskii rinosinusit: etiologiya, patoge-nez, klinika, diagnostika i printsipy lecheniya: uchebnoe posobie. Moscow: Meditsinskoe informatsionnoe agenstvo; 2011. (In Russ).

[6] Лопатин А.С., Гамов В.П. Острый и хронический риносинусит: этиология, патогенез, клиника, диагностика и прин-ципы лечения: учебное пособие. М.: Меди-цинское информационное агенство, 2011.

[7] 4.Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004; 130(6):794-6. doi:10.1016/j.otohns.2003.12.003.

[8] Anon J.B., Jacobs M.R., Poole M.D., et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis // Otolaryngol. Head Neck Surg. 2004. Vol. 130, №6. P. 794-796. doi:10.1016/j.otohns. 2003.12.003.

[9] 5.Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):72-112.

[10] Chow A.W., Benninger M.S., Brook I., et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults // Clin. Infect. Dis. 2012. Vol. 54, №8. P. 72-112.

[11] 6.Svistushkin VM, Savvateeva DM. Current trends in the treatment of acute rhinosinusitis. Russkij medicinskij zhurnal. 2016; 4:251-4. (In Russ).

[12] Свистушкин В.М., Савватеева Д.М. Современные тенденции в лечении пациентов с острым риносинуситом // РМЖ. 2016. №4. P. 251-254.

[13] 7.Turovskiy AB, Karyuk YuA, Kondrashina VV. Antibakterial'naya terapiya infektsiy LOR-organov. Klinitsist. 2013; 3(4):98-103. (In Russ).

[14] Туровский А.Б., Карюк Ю.А., Кондрашина В.В. Антибактериальная терапия инфекций ЛОР-органов // Клиницист. 2013. Т. 3, №4. С. 98-103.

[15] 8.Jakovlev SV, Sidorenko SV, Rafal'skij VV, et al, editors. Strategija i tak-tika racional'nogo primenenija antimikrobnyh sredstv v ambulatornoj praktike: Evrazijskie klinicheskie rekomendacii. Moscow: Pre100 Print; 2016. (In Russ).

[16] Яковлев С.В., Сидоренко С.В., Рафальский В.В., и др., ред. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике: Евразийские клинические рекомендации. М.: Пре100 Принт, 2016.

[17] 9.Abdulkerimov KhT, Garashchenko TI, Koshel' VI, et al.; Ryazantsev SV, editor. Printsipy etiopatogeneticheskoi terapii ostrykh sinusitov: metodicheskie rekomendatsii. Saint-Petersburg: Poliforum Grupp; 2014. (In Russ).

[18] Абдулкеримов Х.Т., Гаращенко Т.И., Кошель В.И., и др.; Рязанцев С.В., ред. Принципы этиопатогенетической тера-пии острых синуситов: методические реко-мендации. СПб.: Полифорум Групп, 2014.

[19] 10.Hansen J.G., Schmidt H., Grinsted P. Randomized, double blind, placebo controlled trial of penicillin V in the treatment of acute maxillary sinusitis in adults in general practice. Scand J Prim Health Care. 2000; 18(1):44-7.

[20] Hansen J.G., Schmidt H., Grinsted P. Randomized, double blind, placebo controlled trial of penicillin V in the treatment of acute maxillary sinusitis in adults in general practice // Scand. J. Prim. Health Care. 2000. Vol. 18, №1. P. 44-47.

[21] 11.Hickner JM, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med. 2001; 134(6):498-505.

[22] Hickner J.M., Bartlett J.G., Besser R.E., et al. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background // Ann. Intern. Med. 2001. Vol. 134, №6. P. 498-505.

[23] 12.Lund VJ. Therapeutic Targets in Rhinosinusitis: Infection or Inflammation? Medscape J Med. 2008; 10(4):105.

[24] Lund V.J. Therapeutic Targets in Rhinosinusitis: Infection or Inflammation? // Medscape J. Med. 2008. Vol. 10, №4. P. 105.

[25] 13.Van Buchem FL, Knottnerus JA, Schrijnemaekers VJ, et al. Primary-care-based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis. Lancet. 1997;349:683-7.

[26] Van Buchem F.L., Knottnerus J.A., Schrijnemaekers V.J., et al. Primary-care-based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis // Lancet. 1997. Vol. 349. P. 683-687.

[27] 14.Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol. 2005; 116:1289-95.

[28] Meltzer E.O., Bachert C., Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo // J. Allergy Clin. Immunol. 2005. Vol. 116. P. 1289-1295.

[29] 15.Lin AN, Paget SA. Principles of Corticosteroid Therapy. Arnold; 2002.

[30] Lin A.N., Paget S.A. Principles of Corticosteroid Therapy. Arnold, 2002.

[31] 16.Hochhaus G. Pharmacokinetic / pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy. Clin Ther. 2008; 30:1-13.

[32] Hochhaus G. Pharmacokinetic / pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy // Clin. Ther. 2008. Vol. 30. P. 1-13.

[33] 17.Allen DB. Systemic effects of intranasal corticosteroids: an endocrinologist's perspective. J Allergy Clin Immunol. 2000; 106(4):179-90.

[34] Allen D.B. Systemic effects of intranasal corticosteroids: an endocrinologist's perspective // J. Allergy Clin. Immunol. 2000. Vol. 106, №4. P. 179-190.

[35] 18.Williamson IG, Rumsby K, Benge S, et al. Antibiotics and topical nasal steroid for treatment of acute maxillary sinusitis. JAMA. 2007; 298:2487-96.

[36] Williamson I.G., Rumsby K., Benge S., et al. Antibiotics and topical nasal steroid for treatment of acute maxillary sinusitis // J.A.M.A. 2007. Vol. 298. P. 2487-2496.

[37] 19.Mygind N, Nielsen LP, Hoffmann HJ, et al. Mode of action of intranasal corticosteroids. J Allergy Clin Immunol. 2001; 108(Suppl 1):S16-S25.

[38] Mygind N., Nielsen L.P., Hoffmann H.J., et al. Mode of action of intranasal corticosteroids // J. Allergy Clin. Immunol. 2001. Vol. 108, Suppl. 1. P. S16-S25.

[39] 20.Novikova L, Baranova O, Ilkovich Yu. Use of acetylcysteine in clinical pulmonology. Vrach. 2014; 2:13-6. (In Russ).

[40] Новикова Л., Баранова О., Илькович Ю. Применение ацетилцистеина в клинической пульмонологии // Врач. 2014. №2. С. 13-16.

[41] 21.Zheng СН, Ahmed К, Rikicomi N, et al. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol. Immunol. 1999; 43(2): 107-13.

[42] Zheng С.Н., Ahmed К., Rikicomi N., et al. The effects of S-carboxy-methylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells // Microbiol. Immunol. 1999. Vol. 43, №2. P. 107-113.

[43] 22.Karpova EP, Tulupov DA. On The Possibilities of Nebuliser Therapy In The Treatment of Acute Rhinosinusitis In Children. Rossiiskaya otorinolaringologiya. 2013; 4(65):160-3. (In Russ).

[44] Карпова Е.П., Тулупов Д.А. О возможностях небулайзерной терапии в лечении острых риносинуситов у детей // Российская оториноларингология. 2013. Т. 65, №4. С. 160-163.

[45] 23.Lopatin AS, editor. Ostryj rinosinu-sit: klinicheskie rekomendacii. Moscow: Rossi-jskoe obshhestvo rinologov; 2017. (In Russ).

[46] Лопатин А.С., ред. Острый риносинусит: клинические рекомендации. М.: Российское общество ринологов, 2017.

[47] 24.Pshennikov DS, Angotoeva IB. The prospects for inhalation therapy of rhino-sinusitis. Nauka molodykh (Eruditio Juve-nium). 2017; 2:277-82. doi:10.23888/HMJ 20172277-282.

[48] Пшенников Д.С., Анготоева И.Б. Перспективы ингаляционной терапии острого риносинусита // Наука молодых (Eruditio Juvenium). 2017. Т. 5, №2. С. 277-282. doi:10.23888/HMJ20172277-282.

[49] Mezhevikina GS, Morozova SI, Savelyeva NA, et al. Modern technologies of treatment of candidiasis of oral mucosa. Rossijskiy mediko-biologicheskiy vestnik imeni akademika I.P. Pavlova. 2012;20 (4):158-163. doi:10.17816/PAVLOVJ20124-158-163.

[50] Межевикина Г.С., Морозова С.И., Савельева Н.А., и др. Современные технологии лечения кандидоза слизистой оболочки рта // Российский медико-биологический вестник имени академика И.П. Павлова. 2012. Т. 20, №4. С. 158-163. doi: 10.17816/PAVLOVJ20124158-163.

RIGHTS & PERMISSIONS

Pshennikov D.S., Angotoeva I.B.